Yahoo
Shanghai - Delayed Quote CNY

Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS)

24.81 -1.73 (-6.52%)
At close: October 30 at 3:00:01 PM GMT+8
Chart Range Bar
Loading chart for 603590.SS
  • Previous Close 26.54
  • Open 25.19
  • Bid 24.81 x --
  • Ask 24.82 x --
  • Day's Range 24.57 - 25.98
  • 52 Week Range 24.57 - 50.76
  • Volume 3,686,846
  • Avg. Volume 2,842,850
  • Market Cap (intraday) 4.001B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 23.19
  • EPS (TTM) 1.07
  • Earnings Date --
  • Forward Dividend & Yield 0.35 (1.41%)
  • Ex-Dividend Date Jul 8, 2026
  • 1y Target Est --

Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon halys hemocoagulase under Suling trade name. It is also involved in the development of drug candidates, including ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; and KC1036, which is in phase 2 clinical trial for the treatment of solid tumors. The company was founded in 2003 and is headquartered in Beijing, China.

www.konruns.cn

793

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

603590.SS
36.90%
SSE Composite Index (000001.SS)
9.32%

1-Year Return

603590.SS
46.67%
SSE Composite Index (000001.SS)
9.73%

3-Year Return

603590.SS
34.80%
SSE Composite Index (000001.SS)
19.11%

5-Year Return

603590.SS
15.01%
SSE Composite Index (000001.SS)
1.46%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    15.97%

  • Return on Assets (ttm)

    2.29%

  • Return on Equity (ttm)

    4.00%

  • Revenue (ttm)

    863.12M

  • Net Income Avi to Common (ttm)

    137.89M

  • Diluted EPS (ttm)

    1.07

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    799.76M

  • Total Debt/Equity (mrq)

    10.95%

  • Levered Free Cash Flow (ttm)

    -88.24M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: